Compare SGC & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGC | IVVD |
|---|---|---|
| Founded | 1920 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.8M | 201.9M |
| IPO Year | 1994 | 2021 |
| Metric | SGC | IVVD |
|---|---|---|
| Price | $13.98 | $0.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $16.00 | $8.75 |
| AVG Volume (30 Days) | 44.1K | ★ 2.9M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.93% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $566,184,000.00 | $53,426,000.00 |
| Revenue This Year | $3.23 | $61.57 |
| Revenue Next Year | $3.82 | $41.42 |
| P/E Ratio | $100.93 | ★ N/A |
| Revenue Growth | 0.09 | ★ 110.47 |
| 52 Week Low | $8.30 | $0.49 |
| 52 Week High | $14.59 | $3.07 |
| Indicator | SGC | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 61.28 | 45.20 |
| Support Level | $9.76 | N/A |
| Resistance Level | $14.59 | $1.01 |
| Average True Range (ATR) | 0.65 | 0.06 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 84.71 | 54.19 |
Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.